Which stocks to buy, hold or sell today? As Dalal Street enters the May 15 session, here's a look at what brokerages make of some of the key stocks in focus. On their radar are stocks such as Tata Motors, DLF, Cipla and Indraprastha Gas.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Do you have any of these stocks in your portfolio?

Cipla shares

Brokerages are divided on Cipla after the drug maker's earnings announcement, with targets ranging from Rs 875 to Rs 1,271.   

Brokerage Rating Target price
JPMorgan Overweight Raised to Rs 1,050 from Rs 1,030
Bernstein Outperform Raised to Rs 1,271 from Rs 1,234
Citi Buy Reduced to Rs 1,110 from Rs 1,140
Goldman Sachs Sell Reduced to Rs 875 from Rs 900
Macquarie Outperform Rs 1,050
Nomura Buy Rs 1,036

IGL shares

Brokerage Rating Target price
JPMorgan Neutral Raised to Rs 460 from Rs 420
Jefferies Buy Raised to Rs 560 from Rs 540
Macquarie Neutral Rs 450

DLF shares

CLSA (buy), JPMorgan (overweight), Jefferies (buy) and Citi (sell) raised their target prices for the realty developer's stock by Rs 82-75 apiece. 

Brokerage Rating Target price
CLSA Buy Raised to Rs 540 from Rs 458
JPMorgan Overweight Raised to Rs 510 from Rs 490
Jefferies Buy Raised to Rs 510 from Rs 435
Citi Sell Raised to Rs 320 from Rs 268

Tata Motors shares

Tata Motors' net profit and EBITDA exceeded Goldman Sachs's estimates by 105 per cent and six per cent respectively. According to the brokerage, Jaguar Land Rover's margin surprised on the upside driven by a favourable mix, pricing and the progress on lean initiatives. 

Goldman Sachs raised its target price for Tata Motors by Rs 50 to Rs 600.

Brokerage Rating Target price
Goldman Sachs Buy Raised to Rs 600 from Rs 550
CLSA Buy Raised to Rs 624 from Rs 544
JPMorgan Neutral Raised to Rs 455 from Rs 415
Jefferies Buy Raised to Rs 655 from Rs 600
Nomura Buy Raised to Rs 610 from Rs 508

Manappuram Finance shares 

According to Morgan Stanley, Manappuram Finance's loan growth in the quarter ended March 2023 came as a positive surprise given a sharp surge in gold loan yields. 

Brokerage Rating Target price
CLSA Buy Rs 140
BofA Buy Rs 143
Morgan Stanley Overweight Rs 160

Colgate-Palmolive shares

Brokerage Rating Target price
CLSA Buy Raised to Rs 1,610 from Rs 1,515
Nomura Buy Raised to 1,650 from Rs 1,550
Goldman Sachs Neutral Raised to Rs 1,500 from Rs 1,330
JPMorgan Buy Raised to Rs 1,750 from Rs 1,645
Jefferies Buy Raised to Rs 1,850 from Rs 1,750

Dr Lal Pathlabs shares

Brokerage Rating Target price
Credit Suisse Underperform Raised to Rs 1,600 from Rs 1,500
Nomura Neutral Reduced to RS 1,835 from Rs 1,864
Morgan Stanley Equal-weight Rs 2,214

According to Morgan Stanley, near-term growth for the company is likely to be aided by geographical diversification and higher pricing. The brokerage has maintained its rating citing the declining trajectory of Dr Lal's EBITDA margin. 

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.